Found 0 matching trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) PHASE2 This was a study to investigate the potential clinical benefit of trilacicl...
Show More Location
Arizona Oncology Associates, PC - HOPE
Learn More & Join Trial
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients PHASE3 A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study ...
Show More Location
Jilin Cancer Hopspital
Learn More & Join Trial
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer PHASE2 To observe the incidence of chemotherapy-induced myelosuppression and the s...
Show More Location
The Affiliated Hospital of Nanjing University Medical School
Learn More & Join Trial
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. PHASE3 The aim of this study is to see whether the Trilaciclib is safe and effecti...
Show More Location
Nanfang Hospital, Southern Medical University
Learn More & Join Trial
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer PHASE2 The purpose of this study is to further advance the ability to practice per...
Show More Location
University of Alabama at Birmingham
Learn More & Join Trial
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) PHASE2 This is a randomized, double-blind, placebo-controlled, global, multicenter...
Show More Location
Ironwood Cancer & Research Centers
Learn More & Join Trial
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib PHASE2 This study is a single arm, exploratory clinical study aimed at evaluating ...
Show More Status
Enrolling By Invitation
Location
Henan Tumor Hospital
Learn More & Join Trial
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) PHASE2 This study is a prospective, single arm phase II clinical trial aimed at pa...
Show More Location
The First Affiliated Hospital of Xiamen University
Learn More & Join Trial
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC PHASE2 This study is a prospective, single arm phase II study aimed at patients wi...
Show More Location
The First Affiliated Hospital of Xiamen University
Learn More & Join Trial
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC PHASE2 The aim of this study is to investigate the safety and efficacy of the prop...
Show More Location
Taixing People's Hospital
Learn More & Join Trial